Metformin is a prescription drug approved for type 2 diabetes. Over the past decade, researchers have studied it in breast cancer clinical trials after noticing that diabetic patients taking metformin had different cancer outcomes than those who did not. It is not a standard breast cancer therapy today, but more trials are testing it as an addition to chemotherapy and hormonal treatment. Many patients, especially those with insulin resistance or metabolic syndrome, ask their oncologists about it. Patients newly diagnosed with hormone receptor-positive disease can learn more in this guide to reading your pathology report and planning integrative support.
Metformin works by turning on an enzyme called AMPK (adenosine monophosphate-activated protein kinase). AMPK activation stops signals along the PI3K/Akt/mTOR pathway – a growth pathway that many breast cancer cells use. Metformin also lowers circulating insulin and insulin-like growth factor (IGF-1) levels. Elevated insulin is linked to worse breast cancer outcomes in several studies. These two effects – stopping the growth pathway and lowering insulin – are why researchers are studying metformin in breast cancer, as reviewed in a 2024 analysis of metformin and breast cancer findings. Because several supplements in integrative oncology affect the same pathways, it’s important to understand these interactions before combining them with metformin.
| Supplement | Mechanism in Cancer Research | Current Evidence Level | Key Concern With Metformin |
|---|---|---|---|
| Berberine | Activates AMPK; overlaps metformin’s core glucose-lowering and antiproliferative pathway | Preclinical and early metabolic clinical data | Additive blood glucose lowering; may increase hypoglycemia risk in non-diabetic patients |
| Curcumin (BCM-95) | Anti-inflammatory; inhibited angiogenesis and triggered apoptosis in a breast cancer mouse model | Preclinical (mouse model; no large human RCT) | Inhibits CYP3A4 and CYP2C9 liver enzymes; may alter chemotherapy and hormonal therapy metabolism |
| Quercetin | Antioxidant; EGFR-pathway modulation in breast cancer cell studies | Preclinical only | May affect OCT1/OCT2 drug transporters; theoretical impact on metformin blood levels |
| Green Tea Extract (EGCG) | Antioxidant; antiproliferative activity in breast cancer cell-line studies | Preclinical only | Limited human interaction data; disclose high-dose formulations to your care team |
| Vitamin B12 (supplemental) | Not anti-cancer; corrects metformin-associated B12 depletion | Well-established corrective use in metformin-treated patients | Generally well tolerated; dose and monitoring interval should be set by clinician |
Mechanism data sourced from: berberine and metformin comparative review (PMC5839379); curcumin and metformin breast cancer mouse study (PMC5405996); metformin drug-transporter interaction review (PMC5788205). Evidence levels describe quality of available research data, not confirmed clinical benefit in humans.
What Clinical Trials Have Found
The METTEN study is one of the most referenced breast cancer trials of metformin. It was a phase 2 randomized trial in women with early HER2-positive breast cancer. Participants received metformin at 850 mg twice daily alongside standard trastuzumab-based chemotherapy. The pathologic complete response (pCR) rate (the proportion of patients with no residual cancer in the breast after neoadjuvant treatment) was 65.5% in the metformin group versus 58.6% in the control group. This difference was not statistically significant, as reported in the published METTEN trial.
A separate open-label phase 2 randomized controlled trial tested metformin added to neoadjuvant chemotherapy in non-metastatic triple negative breast cancer (TNBC). TNBC has no estrogen receptors, progesterone receptors, or HER2 amplification, which limits available targeted therapy options. Early reporting from this trial has been published, as recorded in its protocol and early results, though confirmatory data from larger trials are still pending. A smaller RCT in locally advanced breast cancer found a better radiologic response to neoadjuvant chemotherapy in the metformin group compared to controls, as published in a 2022 PMC study.
Across these trials, metformin’s benefit varies by breast cancer subtype and by the patient’s metabolic profile. Patients with higher fasting insulin or insulin resistance may benefit most from metformin’s effect on insulin. Metformin is not approved for breast cancer treatment, and there is not yet enough evidence to use it outside of clinical trials. The strongest next step for an interested patient is to ask their oncologist whether a relevant clinical trial is currently enrolling.
Dosing Used in Breast Cancer Research
Across published breast cancer trials, metformin doses have ranged from 500 mg daily to 2,250 mg daily. The METTEN study used 850 mg twice daily (1,700 mg total per day). Many integrative oncology protocols start at 500 mg once daily with food, then increase to 500 mg two or three times daily over two to four weeks. Slow titration reduces gastrointestinal side effects – nausea, loose stools, and stomach cramps – that are common in the first few weeks. Taking metformin consistently with a meal also helps with tolerability.
Metformin is prescription-only. Dosing must be set by the clinician who reviews your kidney function, full medication list, and metabolic lab values. Patients who have already received a prescription and need a consistent supply can check availability of Oncostore’s Gmcare PR 500 (Metformin 500mg). Oncostore is a pharmacy, not a prescribing service – a valid prescription is required.
Supplement Interactions: A Closer Look
The table above gives an overview. The sections below provide more detail. None of this constitutes a recommendation to combine these compounds with metformin without clinician review.
Berberine
Berberine is a plant-derived alkaloid found in herbs including barberry and Oregon grape. It activates AMPK – the same enzyme that metformin targets. A 2018 review published in PMC compared berberine and metformin across multiple mechanisms. The authors found that both drugs inhibit mTOR signaling and slow cancer cell proliferation in similar ways, and that berberine produced effects on cellular ATP levels that matched those seen with metformin, as reported in that analysis. In metabolic trials, berberine is typically studied at 500 mg taken one to three times daily. Because berberine and metformin share the same main pathway, combining them may increase blood glucose lowering enough to cause low blood sugar in some patients – especially if you don’t have diabetes. Always inform your oncologist if you are using berberine.
Curcumin
Curcumin is the active polyphenol in turmeric. A 2017 preclinical study tested metformin combined with curcumin in a mouse model of breast cancer. The combination slowed tumor growth more than either compound alone, affecting angiogenesis and apoptosis, as reported in that PMC publication. This is a mouse model finding and does not confirm the same effect in humans. The practical concern with curcumin in an oncology setting is its effect on liver enzymes. Curcumin inhibits CYP3A4 and CYP2C9 – enzymes that break down tamoxifen, some aromatase inhibitors, and taxane chemotherapy agents. Inhibiting these enzymes can raise drug blood levels and may alter toxicity. Patients on tamoxifen or taxane regimens should discuss curcumin with their oncologist before using it. For more detail on curcumin dosing in the breast cancer context, see the article on aromatase inhibitor joint pain and curcumin dosing.
Quercetin and Green Tea Extract (EGCG)
Quercetin is a flavonoid found in onions, apples, and capers, and is available in supplements at 1 g doses. EGCG is the main polyphenol in green tea extract. Both have been studied in breast cancer cell lines for antiproliferative and antioxidant properties. Few human trials have tested either compound with metformin in breast cancer. A pharmacokinetic concern with quercetin involves the OCT1 and OCT2 drug transporters that control how your body absorbs and removes metformin. Quercetin can affect OCT function, which means high-dose quercetin might alter metformin blood levels – though this hasn’t been proven in cancer patients. Disclose high-dose quercetin (above 500 mg per day) or high-dose EGCG use to your oncologist. Learn more about these compounds during immunotherapy at Quercetin and Green Tea During Lung Cancer Immunotherapy.
Safety Monitoring on Metformin During Cancer Treatment
Vitamin B12 Depletion
Metformin interferes with how your body absorbs vitamin B12 in the small intestine. In a 29-week clinical trial, approximately 7% of patients on metformin had low B12 levels, according to the FDA prescribing information accessed via DailyMed. B12 deficiency can cause fatigue, peripheral tingling, and anemia – symptoms that can overlap with and worsen chemotherapy side effects, making the source harder to identify. Ask your care team about periodic B12 testing and supplementation. A 2025 pharmacovigilance study also found that combining metformin with proton pump inhibitors (commonly used to manage chemotherapy-related reflux) increased the risk of serious B12-deficiency-related complications, as reported in that PMC analysis.
Lactic Acidosis
Lactic acidosis can happen but is rare and serious. Doctors estimate approximately 3 cases per 100,000 patient-years, as cited in a published drug-interaction review of metformin. The risk is higher if you have reduced kidney function, liver disease, heart failure, or severe dehydration. Platinum-based chemotherapy agents such as cisplatin and carboplatin can damage kidneys and temporarily reduce kidney function. Patients on both metformin and nephrotoxic chemotherapy need closer monitoring. Doctors usually stop metformin before contrast-enhanced CT scans because iodinated contrast can temporarily impair kidney clearance. Your oncology and imaging teams should coordinate on the timing of holds and restarts.
Kidney Function Thresholds
Doctors do not recommend metformin when eGFR falls below 30 mL/min/1.73 m2, and recommend caution when eGFR is between 30 and 45. Cancer treatment can affect kidney function over time, so your doctor needs to check your eGFR regularly if you’re on metformin throughout your treatment course.
Questions to Bring to Your Oncologist
- Does my breast cancer subtype have supporting trial evidence for metformin as an adjunct?
- Am I eligible for a clinical trial that includes metformin in the treatment arm?
- Do I have elevated fasting insulin or insulin resistance that makes metformin relevant to my metabolic profile?
- Should I have baseline and periodic B12 and eGFR tests while on metformin?
- Are any supplements I currently take – including berberine, curcumin, or quercetin – likely to interact with metformin?
- Should metformin be held before my next imaging scan or any upcoming chemotherapy infusion?
Patients exploring integrative approaches alongside conventional treatment can learn about available formulations at Oncostore’s integrative oncology section, which includes clinician-directed formulations of metformin and other nutraceuticals. All dispensing requires a valid prescription where legally required.
If you are currently on prescription medications, pregnant, or breastfeeding, talk to your care team before starting or changing any supplement or drug. This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
